Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer |
| |
| Authors: | Scott Saxman Patrick J. Loehrer Sr. Keith Logie Doyle Stephens Frank Workman Daniel Scullin Lawrence H. Einhorn Rafat Ansari |
| |
| Affiliation: | (1) Department of Medicine, Indiana University, Indianapolis, IN, USA;(2) Oncology & Hematology Associates, Inc., Indianapolis, IN, USA;(3) Medical Oncology Consultants, Muncie, IN, USA;(4) Memorial Clinic of Indianapolis, Indianapolis, IN, USA;(5) Dobbs, Grimaldi, Scullin & Dannaher, Louisville, KY, USA;(6) Michiana Hematology-Oncology, P.C., South Bend, IN, USA;(7) Indiana University Medical Center, University Hospital, A109, 926 W. Michigan, 46202 Indianapolis, IN, USA |
| |
| Abstract: | Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1–5 day intravenous etoposide administration.from the Hoosier Oncology Group, the Walther Cancer Institute, Indianapolis, IN; Department of Medicine, Indiana University, Indianapolis, IN, USADr. Einhorn is the Walther American Cancer Society Professor of Clinical Oncology. |
| |
| Keywords: | lung cancer etoposide |
| 本文献已被 SpringerLink 等数据库收录！ |
|
